Heron Therapeutics, Inc. (HRTX) Shares Bought by Tudor Investment Corp ET AL

Tudor Investment Corp ET AL boosted its position in Heron Therapeutics, Inc. (NASDAQ:HRTX) by 10.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 18,618 shares of the biotechnology company’s stock after purchasing an additional 1,724 shares during the period. Tudor Investment Corp ET AL’s holdings in Heron Therapeutics were worth $258,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Legal & General Group Plc lifted its stake in Heron Therapeutics by 13.9% in the first quarter. Legal & General Group Plc now owns 8,971 shares of the biotechnology company’s stock valued at $136,000 after purchasing an additional 1,098 shares during the last quarter. Quantbot Technologies LP lifted its stake in Heron Therapeutics by 2,619.6% in the second quarter. Quantbot Technologies LP now owns 12,483 shares of the biotechnology company’s stock valued at $172,000 after purchasing an additional 12,024 shares during the last quarter. HighTower Advisors LLC lifted its stake in Heron Therapeutics by 11.4% in the second quarter. HighTower Advisors LLC now owns 16,584 shares of the biotechnology company’s stock valued at $231,000 after purchasing an additional 1,700 shares during the last quarter. Voya Investment Management LLC lifted its stake in Heron Therapeutics by 44.4% in the second quarter. Voya Investment Management LLC now owns 20,377 shares of the biotechnology company’s stock valued at $282,000 after purchasing an additional 6,267 shares during the last quarter. Finally, Nationwide Fund Advisors lifted its stake in Heron Therapeutics by 11.3% in the first quarter. Nationwide Fund Advisors now owns 21,972 shares of the biotechnology company’s stock valued at $330,000 after purchasing an additional 2,233 shares during the last quarter.

Shares of Heron Therapeutics, Inc. (NASDAQ HRTX) opened at 15.40 on Monday. The firm’s 50 day moving average price is $15.97 and its 200 day moving average price is $15.18. Heron Therapeutics, Inc. has a 52-week low of $12.21 and a 52-week high of $20.85. The stock’s market cap is $833.73 million.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.80) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.90) by $0.10. The business had revenue of $8.51 million for the quarter, compared to analysts’ expectations of $4.53 million. On average, analysts expect that Heron Therapeutics, Inc. will post ($3.51) EPS for the current year.

WARNING: This story was originally reported by Transcript Daily and is owned by of Transcript Daily. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://transcriptdaily.com/2017/10/16/heron-therapeutics-inc-hrtx-shares-bought-by-tudor-investment-corp-et-al.html.

HRTX has been the topic of several research analyst reports. ValuEngine upgraded Heron Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Thursday, June 22nd. Cantor Fitzgerald restated an “overweight” rating on shares of Heron Therapeutics in a research report on Monday, June 26th. Zacks Investment Research upgraded Heron Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 target price on the stock in a research report on Wednesday, July 12th. Jefferies Group LLC restated a “buy” rating and set a $26.00 target price on shares of Heron Therapeutics in a research report on Friday, July 14th. Finally, Aegis restated a “buy” rating and set a $33.00 target price on shares of Heron Therapeutics in a research report on Tuesday, July 18th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have assigned a buy rating to the stock. Heron Therapeutics presently has an average rating of “Buy” and an average target price of $28.50.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Want to see what other hedge funds are holding HRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heron Therapeutics, Inc. (NASDAQ:HRTX).

Institutional Ownership by Quarter for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply